Information Provided By:
Fly News Breaks for November 30, 2017
NEO
Nov 30, 2017 | 09:14 EDT
Gabelli analyst Sara Wojda named NeoGenomics a best idea for 2018 citing double-digit volume growth combined with double-digit reduction in cost per test, contined share gains in the core clinical services division, and expectations for stabilization in pricing for FISH tests. Wojda rates NeoGenomics a Buy with a $12 PMV.
News For NEO From the Last 2 Days
There are no results for your query NEO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.